MA46620A - Composés hétérobicycliques utiles en tant que modulateurs de réponses à il-12, il-23 et/ou ifn alpha - Google Patents
Composés hétérobicycliques utiles en tant que modulateurs de réponses à il-12, il-23 et/ou ifn alphaInfo
- Publication number
- MA46620A MA46620A MA046620A MA46620A MA46620A MA 46620 A MA46620 A MA 46620A MA 046620 A MA046620 A MA 046620A MA 46620 A MA46620 A MA 46620A MA 46620 A MA46620 A MA 46620A
- Authority
- MA
- Morocco
- Prior art keywords
- modulators
- responses
- useful
- ifn alpha
- heterobicyclic compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662414158P | 2016-10-28 | 2016-10-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA46620A true MA46620A (fr) | 2021-05-26 |
Family
ID=60263169
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA046620A MA46620A (fr) | 2016-10-28 | 2017-10-27 | Composés hétérobicycliques utiles en tant que modulateurs de réponses à il-12, il-23 et/ou ifn alpha |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10781215B2 (enExample) |
| EP (1) | EP3532473B1 (enExample) |
| JP (1) | JP7145850B2 (enExample) |
| KR (1) | KR102477063B1 (enExample) |
| CN (1) | CN110114357B (enExample) |
| ES (1) | ES2895107T3 (enExample) |
| MA (1) | MA46620A (enExample) |
| WO (1) | WO2018081488A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7082120B2 (ja) | 2016-10-21 | 2022-06-07 | ニンバス ラクシュミ， インコーポレイテッド | Ｔｙｋ２阻害剤およびその使用 |
| US10508113B2 (en) | 2018-03-12 | 2019-12-17 | Abbvie Inc. | Inhibitors of tyrosine kinase 2 mediated signaling |
| AR117177A1 (es) * | 2018-12-10 | 2021-07-14 | Lilly Co Eli | DERIVADOS DE 7-(METILAMINO)PIRAZOLO[1,5-A]PIRIMIDIN-3-CARBOXAMIDA COMO INHIBIDORES DE IL-23 E INFa |
| CN111484480B (zh) * | 2019-01-29 | 2023-08-11 | 上海翰森生物医药科技有限公司 | 一种多环类衍生物抑制剂、其制备方法和应用 |
| EA202192625A1 (ru) * | 2019-03-26 | 2022-03-21 | Вентикс Байосайенсес, Инк. | Лиганды псевдокиназы tyk2 |
| CN114269336A (zh) | 2019-04-30 | 2022-04-01 | 细胞基因公司 | 包含阿普斯特和tyk2抑制剂的联合疗法 |
| KR102938141B1 (ko) | 2019-11-08 | 2026-03-11 | 벤틱스 바이오사이언스, 인크. | Tyk2 슈도키나제 리간드 |
| WO2021108803A1 (en) * | 2019-11-26 | 2021-06-03 | Theravance Biopharma R&D Ip, Llc | Fused pyrimidine pyridinone compounds as jak inhibitors |
| CN116283993B (zh) * | 2021-12-20 | 2024-05-03 | 艾立康药业股份有限公司 | 一种嘧啶类化合物及其制备方法和应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7176214B2 (en) | 2003-05-21 | 2007-02-13 | Bristol-Myers Squibb Company | Imidazo-fused oxazolo[4,5-β]pyridine and imidazo-fused thiazolo[4,5-β]pyridine based tricyclic compounds and pharmaceutical compositions comprising same |
| WO2008135232A1 (en) | 2007-05-02 | 2008-11-13 | Riccardo Cortese | Use and compositions of purine derivatives for the treatment of proliferative disorders |
| RU2472797C2 (ru) * | 2007-08-08 | 2013-01-20 | ГЛАКСОСМИТКЛАЙН ЭлЭлСи | ПРОИЗВОДНЫЕ 2-[(2-(ФЕНИЛАМИНО)-1Н-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)АМИНО]БЕНЗАМИДА В КАЧЕСТВЕ ИНГИБИТОРОВ IGF-1R ДЛЯ ЛЕЧЕНИЯ РАКА |
| US8592432B2 (en) * | 2008-04-07 | 2013-11-26 | Bei Chen | Compounds and compositions as protein kinase inhibitors |
| JP2011518219A (ja) * | 2008-04-22 | 2011-06-23 | ポートラ ファーマシューティカルズ， インコーポレイテッド | タンパク質キナーゼの阻害剤 |
| CA2890935A1 (en) * | 2012-11-08 | 2014-05-15 | Bristol-Myers Squibb Company | Alkyl amide-substituted pyrimidine compounds useful in the modulation of il-12, il-23 and/or ifn.alpha. |
| AR094537A1 (es) | 2013-11-07 | 2015-08-12 | Bristol Myers Squibb Co | COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa |
| EP3080131B1 (en) * | 2013-12-10 | 2018-10-10 | Bristol-Myers Squibb Company | Imidazopyridazine compounds useful as modulators of il-12, il-23 and/or ifn alpha responses |
| TW201625620A (zh) * | 2014-05-14 | 2016-07-16 | 美國科羅拉多州立大學 | 作為蛋白去乙醯酶抑制劑及雙蛋白去乙醯酶蛋白激酶抑制劑之雜環氧肟酸及其使用方法 |
| JP7082120B2 (ja) * | 2016-10-21 | 2022-06-07 | ニンバス ラクシュミ， インコーポレイテッド | Ｔｙｋ２阻害剤およびその使用 |
-
2017
- 2017-10-27 KR KR1020197014828A patent/KR102477063B1/ko active Active
- 2017-10-27 US US16/344,459 patent/US10781215B2/en active Active
- 2017-10-27 MA MA046620A patent/MA46620A/fr unknown
- 2017-10-27 JP JP2019522803A patent/JP7145850B2/ja active Active
- 2017-10-27 ES ES17794645T patent/ES2895107T3/es active Active
- 2017-10-27 WO PCT/US2017/058645 patent/WO2018081488A1/en not_active Ceased
- 2017-10-27 CN CN201780080803.4A patent/CN110114357B/zh active Active
- 2017-10-27 EP EP17794645.6A patent/EP3532473B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN110114357B (zh) | 2022-05-31 |
| ES2895107T3 (es) | 2022-02-17 |
| KR102477063B1 (ko) | 2022-12-12 |
| JP2019532092A (ja) | 2019-11-07 |
| US20190322672A1 (en) | 2019-10-24 |
| CN110114357A (zh) | 2019-08-09 |
| JP7145850B2 (ja) | 2022-10-03 |
| US10781215B2 (en) | 2020-09-22 |
| KR20190068614A (ko) | 2019-06-18 |
| WO2018081488A1 (en) | 2018-05-03 |
| EP3532473B1 (en) | 2021-09-29 |
| EP3532473A1 (en) | 2019-09-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA46453A (fr) | Composés imidazopyridazine utiles en tant que modulateurs de réponses il-12, il-23 et/ou ifn alpha | |
| EP3383447A4 (en) | LIGHT-ACTIVATED HYDROGEL PRODUCTION | |
| PT3523390T (pt) | Utilização de composições à base de tetrafluoropropeno | |
| EP3493799A4 (en) | CANNABIS | |
| EP3509581A4 (en) | FORMULATIONS OF (R | |
| MA43512A (fr) | Composés hétérocycliques utiles en tant que modulateurs du tnf alpha | |
| FIC20260013I1 (fi) | ikodekinsuliini ja semaglutidi | |
| BR112016025470A2 (pt) | ?hdl terapêutico? | |
| EP3474667A4 (en) | SMALL MOLECULAR MODULATORS OF PANTOTHENAT KINASES | |
| EP3483213A4 (en) | ACRLYKAUTSCHUKZUSAMMENSETZUNG | |
| MA48602A (fr) | Composés hétéroaryle substitués par un amide alkyle d'oxyde de phosphine en tant que modulateurs des réponses il-12, il-23 et/ou ifn alpha | |
| MX389001B (es) | Moduladores de interacción de sestrina-gator2 y sus usos. | |
| PL3293188T3 (pl) | Silany i utwardzalne kompozycje obejmujące wskazane silany | |
| MA43705A (fr) | Formulation pharmaceutique | |
| EP3528813A4 (en) | P2X3 AND / OR P2X2 / 3 CONNECTIONS AND METHOD | |
| EP3400026A4 (en) | VISCOSITY AND STABILITY-MODIFIED ULTRASOUND GEL | |
| MA43314A (fr) | Vecteurs de grippe atténues utilisés pour la prophylaxie et/ou le traitement de maladies infectieuses ainsi que pour le traitement de maladies oncologiques | |
| CL2016001763A1 (es) | Antagonistas selectivos de nr2b | |
| MA44772A (fr) | 6-aminopyridine-3-yl thiazoles utilisés en tant que modulateurs de ror t | |
| EP3328368A4 (en) | COMPOUNDS AND PHARMACEUTICAL COMPOSITION RELATING TO THE UBIQUITINATION PROTEASOM SYSTEM | |
| EP3316879A4 (en) | TOPICAL DIACEREIN OR RHEIN FORMULATIONS AND USES THEREOF | |
| EP3897615A4 (en) | CANNABIS COMPOSITIONS AND METHODS | |
| EP3512521A4 (en) | PHARMACEUTICAL CLOZAPINE COMPOSITIONS WITH DELAYED RELEASE | |
| FR3037236B1 (fr) | Microcapsules et composition de maquillage ou de tatouage thermochromiques | |
| MA41120A (fr) | Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci |